Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.94 Insider Own0.30% Shs Outstand72.62M Perf Week1.82%
Market Cap11.13B Forward P/E- EPS next Y-2.96 Insider Trans-45.92% Shs Float70.30M Perf Month28.17%
Income-403.20M PEG- EPS next Q-1.37 Inst Own95.60% Short Float16.74% Perf Quarter27.95%
Sales323.40M P/S34.41 EPS this Y-533.90% Inst Trans-0.03% Short Ratio10.13 Perf Half Y29.22%
Book/sh18.80 P/B8.15 EPS next Y38.20% ROA-26.70% Target Price209.95 Perf Year9.92%
Cash/sh18.51 P/C8.28 EPS next 5Y-0.20% ROE-43.40% 52W Range95.21 - 165.87 Perf YTD40.43%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-7.61% Beta1.98
Dividend %- Quick Ratio11.10 Sales past 5Y84.10% Gross Margin87.40% 52W Low60.96% ATR5.80
Employees499 Current Ratio12.20 Sales Q/Q34.70% Oper. Margin- RSI (14)63.38 Volatility3.09% 4.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-95.30% Profit Margin- Rel Volume0.62 Prev Close156.91
ShortableYes LT Debt/Eq0.32 EarningsAug 07 AMC Payout- Avg Volume1.16M Price153.25
Recom1.70 SMA207.92% SMA5019.36% SMA20020.75% Volume727,589 Change-2.33%
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jul-12-19 08:57AM  Sarepta Therapeutics Looks Ready to Break Out to the Upside
Jul-08-19 09:55AM  Sarepta Stock Up Almost 40% This Year So Far: Here's Why Zacks
Jul-01-19 10:11AM  Sarepta Therapeutics Stock Could Capitalize From Pfizers Stumble
09:35AM  Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues Zacks
09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
09:15AM  Stocks Soar 7% in June Zacks
Jun-28-19 04:30PM  Why CalAmp, Sarepta Therapeutics, and Motorcar Parts of America Jumped Today Motley Fool +17.10%
04:28PM  Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying Investor's Business Daily
04:27PM  Here's Why Sarepta Therapeutics Is Surging Today Motley Fool
01:35PM  Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems
12:28PM  Street Crowns Sarepta DMD Gene Therapy King After Pfizer Results Bloomberg
10:34AM  Sarepta surges after Pfizer gene therapy data raises safety concerns Reuters
10:23AM  Sarepta surges after Pfizer gene therapy data raises safety concerns Reuters
10:18AM  Pfizer gene therapy for rare muscle disease shows promise in small, early study Reuters
Jun-27-19 08:48AM  Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock? Zacks
Jun-24-19 04:14PM  This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data Investor's Business Daily
Jun-18-19 07:08AM  The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Is Up 612% And Shareholders Are Delighted Simply Wall St.
Jun-13-19 10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-10-19 03:44PM  Heres What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT) Insider Monkey
Jun-09-19 07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 09:30AM  Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue? Zacks
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
Jun-04-19 04:30PM  Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
May-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-26-19 03:56AM  Market Weekly Review: Lower Prices Create Buying Opportunities TipRanks
May-14-19 10:38PM  Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
04:27PM  This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note Investor's Business Daily
May-10-19 01:24AM  Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 11:05AM  Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up Zacks
10:44AM  When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St.
May-08-19 05:35PM  Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:26PM  Sarepta Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
02:30PM  Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:30AM  Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy GlobeNewswire
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
May-01-19 04:30PM  Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019 GlobeNewswire
Apr-30-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
Apr-29-19 02:40PM  TripAdvisor CEOs compensation plunged 95 percent in 2018 American City Business Journals
09:11AM  Sarepta CEO's pay dropped 98 percent in 2018 American City Business Journals
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-26-19 07:57AM  Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More Benzinga
Apr-25-19 10:34AM  Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-23-19 07:20AM  3 Stocks Warren Buffett Would Love Motley Fool
Apr-22-19 05:55AM  Pfizer Stock Suffers From an Underappreciated Drugs Pipeline InvestorPlace
Apr-19-19 11:50AM  Here is What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT) Insider Monkey
Apr-17-19 11:10AM  Wave Life Sciences Plunges After DMD Study Data Readout Zacks
Apr-13-19 09:38AM  The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs Benzinga
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
08:30AM  Sarepta Therapeutics Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference GlobeNewswire
Apr-03-19 06:30AM  Ex-Sarepta execs join new Atlas-backed muscular disease startup fueled by $50M American City Business Journals
Mar-29-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-28-19 04:31PM  How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key Market Investor's Business Daily
10:20AM  Sarepta plans second Duchenne drug application this year American City Business Journals
09:21AM  Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug MarketWatch
08:30AM  Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study GlobeNewswire
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-26-19 08:06AM  Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now? Motley Fool
Mar-25-19 07:30AM  Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program GlobeNewswire
Mar-15-19 02:55PM  Sarepta Therapeutics' Charts Look Risky
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos -11.12%
04:37PM  Why NIO, Brown-Forman, and Sarepta Therapeutics Slumped Today Motley Fool
03:39PM  Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today InvestorPlace
08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-05-19 07:32PM  Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock GlobeNewswire
04:02PM  Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock GlobeNewswire
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
Mar-01-19 11:14PM  Edited Transcript of SRPT earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:29PM  Why Big Pharma Is Diving Into Gene Therapy
Feb-28-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
02:09PM  Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development Benzinga
10:54AM  Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up Zacks
09:15AM  Too Much Talking, Not Enough Action Zacks
08:41AM  Sarepta (SRPT) Jumps: Stock Rises 8.3% Zacks
08:30AM  Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program GlobeNewswire
07:13AM  Nationwide Children's gene therapy spinoff acquired for $165M after promising results American City Business Journals
Feb-27-19 11:03PM  Sarepta Therapeutics Inc (SRPT) Q4 2018 Earnings Conference Call Transcript Motley Fool +8.31%
05:29PM  [$$] Sarepta Acquires Gene-Therapy Startup Myonexus Therapeutics for $165 Million The Wall Street Journal
04:21PM  Gene Therapy Space Heats Up As This Biotech Chases Down A Breakout Investor's Business Daily
04:05PM  Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments GlobeNewswire
02:41PM  Sarepta To Pay $165M To Buy Out Myonexus, Reports Positive Results For Muscular Dystrophy Trial Results Benzinga
12:37PM  Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition
10:48AM  Sarepta doubles down on gene therapies after early Limb-Girdle data American City Business Journals
09:00AM  Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
08:37AM  Sarepta stock up 3% after announcing acquisition of gene-therapy company Myonexus MarketWatch
08:00AM  Sarepta to buy Myonexus for $165 mln in gene therapy push Reuters
07:40AM  Sarepta to buy gene therapy developer Myonexus for $165 mln Reuters
07:30AM  Sarepta Exercises Option to Acquire Myonexus Therapeutics GlobeNewswire
Feb-26-19 07:36AM  Jim Cramer Weighs In On Foot Locker, Cisco And More Benzinga
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
09:21AM  MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks
Feb-20-19 04:30PM  Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019 GlobeNewswire
Feb-17-19 08:20AM  3 Top Biotech Stocks to Buy in February Motley Fool
Feb-15-19 08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-14-19 04:01PM  Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A) GlobeNewswire
08:30AM  Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire
Feb-11-19 11:21AM  Weekly CFO Sells Highlight
08:44AM  Implied Volatility Surging for Sarepta (SRPT) Stock Options Zacks
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM
INGRAM DOUGLAS SPresident & CEOAug 15Buy125.2616,0002,004,211399,250Aug 16 07:30 AM